Received Jun 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | — | — |
thymic carcinoma; recurrent breast cancer; This is a spontaneous report received from a Consumer or other non HCP from medical information team. A 76-year-old female patient received BNT162b2 omicron (kp.2) (COMIRNATY (2024-2025 FORMULA)), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Breast cancer female" (ongoing). The patient's concomitant medications were not reported. Vaccination history included: moderna COVID-19 vaccine (DOSE 1, SINGLE, lot number: 006M2014, IM), administration date: 12Feb2021, for COVID-19 immunisation, reaction(s): "Drug ineffective", "Interchange of vaccine products", "COVID-19"; moderna COVID-19 vaccine (DOSE 2, SINGLE, lot number: 0016219, IM), administration date: 12Mar2021, for COVID-19 immunisation; moderna COVID-19 vaccine (DOSE 3 (BOOSTER), SINGLE, lot number: 047C2114, IM), administration date: 22Oct2021, for COVID-19 immunisation, reaction(s): "Drug ineffective", "Interchange of vaccine products", "COVID-19"; BNT162b2 (DOSE 4 (BOOSTER), SINGLE, lot number: FK9895, IM), administration date: 30Mar2022, for COVID-19 immunisation, reaction(s): "Drug ineffective", "Interchange of vaccine products", "COVID-19"; BNT162b2, BNT162b2 omi ba.4-5 (DOSE 5 (BOOSTER), SINGLE), administration date: 09Sep2022, for COVID-19 immunisation, reaction(s): "cold", "sore arm". The following information was reported: THYMIC CARCINOMA (medically significant), outcome "unknown"; BREAST CANCER RECURRENT (medically significant), outcome "unknown", described as "recurrent breast cancer". The patient underwent the following laboratory tests and procedures: Computerised tomogram: Unknown Results; Magnetic resonance imaging: Unknown Results; Positron emission tomogram: thymic carcinoma, notes: thymic carcinoma was identified during PET scan. Therapeutic measures were taken as a result of thymic carcinoma. Clinical course: Caller stated that she had her thymus removed due to a rare form of cancer known as "thymic carcinoma". According to the caller, thymic carcinoma was identified during PET scan, which was performed due to the caller's "recurrent breast cancer", along with an MRI and CAT scan. Caller was informed, by HCP, that "vaccines would not be as effective" with her thymus removed. Caller added that she has received "all eight shots" and that she is 76 years of age. In conclusion, caller was interested in information regarding whether the "potency" of the Pfizer COVID-19 vaccine would be affected due to her thymus having been removed. No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.
Breast cancer female
Test Name: CAT; Result Unstructured Data: Test Result:Unknown Results; Test Name: MRI; Result Unstructured Data: Test Result:Unknown Results; Test Name: PET scan; Result Unstructured Data: Test Result:thymic carcinoma; Comments: thymic carcinoma was identified during PET scan